Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

story of the week

Published in Oncology

Journal Scan / Research · March 21, 2012

Effect of Daily Aspirin on Risk of Cancer Metastasis

The Lancet

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Lee Schwartzberg MD, FACP

The Lancet

Effect of Daily Aspirin on Risk of Cancer Metastasis: A Study of Incident Cancers During Randomised Controlled Trials

Lancet 2012 Mar 21;[EPub Ahead of Print], PM Rothwell, M Wilson, JF Price, JFF Belch, T Meade, Z Mehta

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

featured

2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer

Commentary · December 06, 2022
featured

Impact of Salvage Radiotherapy Initiation at PSA ≤0.5 ng/mL on Survival Outcomes in Patients With Relapsed Prostate Cancer After Prostatectomy

Prostate · November 17, 2022
featured

Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations

Clin. Cancer Res · November 17, 2022
story of the week

PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Lancet Oncol · November 07, 2022
story of the week

Prostate Cancer Aggressiveness and Financial Toxicity in Patients With Prostate Cancer

Prostate · November 01, 2022
featured

VISION Trial Analysis of Time-to-Event Endpoints Associated With Radioligand Therapy

Interview · October 11, 2022
featured

Androgen Annihilation in Patients With High-Risk, Biochemically Relapsed Prostate Cancer

Interview · October 10, 2022
story of the week

Gene-Based Confirmatory Germline Testing Following Tumor-Only Sequencing of Prostate Cancer

Eur Urol · October 06, 2022

updated
featured

Duration of Androgen Deprivation Therapy With Post-Operative Radiotherapy for Prostate Cancer

Interview · October 05, 2022
featured

Abiraterone Plus Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer

Interview · October 04, 2022

Effect of Daily Aspirin on Risk of Cancer Metastasis

Additional Info

Effect of Daily Aspirin on Risk of Cancer Metastasis: A Study of Incident Cancers During Randomised Controlled Trials

Advanced Prostate Cancer Center of Excellence

2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer

Impact of Salvage Radiotherapy Initiation at PSA ≤0.5 ng/mL on Survival Outcomes in Patients With Relapsed Prostate Cancer After Prostatectomy

Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations

PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Aggressiveness and Financial Toxicity in Patients With Prostate Cancer

VISION Trial Analysis of Time-to-Event Endpoints Associated With Radioligand Therapy

Androgen Annihilation in Patients With High-Risk, Biochemically Relapsed Prostate Cancer

Gene-Based Confirmatory Germline Testing Following Tumor-Only Sequencing of Prostate Cancer

Duration of Androgen Deprivation Therapy With Post-Operative Radiotherapy for Prostate Cancer

Abiraterone Plus Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer

Further Reading

Association of Prostate-Specific Antigen Screening With 15-Year Prostate Cancer Mortality

Tissue-Specific Thresholds of Mutation Burden Associated With Anti–PD-1/Anti–PD-L1 Therapy Benefit and Prognosis in Microsatellite-Stable Cancers

Early Incorporation of Palliative Care in Patients With Advanced NSCLC

Remission Induction vs Immediate Allogeneic HSCT for Relapsed or Poorly Responsive AML

Alectinib for Resected ALK-Positive NSCLC

Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Advanced Extranodal Natural Killer/T-Cell Lymphoma

Pembrolizumab Plus Concurrent Chemoradiotherapy for Locally Advanced HNSCC

Preoperative Durvalumab or Durvalumab Plus Tremelimumab for Resectable HNSCC

Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

Association Between Chronic Stress and Metastasis in Patients With Cancer

Recently Updated